Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry

N/AEnrolling By InvitationNCT04279496

Cleerly, Inc.15,000 enrolled

Overview

The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.

CONFIRM2 is a retrospective and prospective, open-label, international, multicenter observational registry designed to evaluate associations between CCTA imaging findings and clinical presentation (cross-sectional) and their ability to predict mortality and major adverse cardiac events (longitudinal) in patients with chronic CAD.

Study Type

OBSERVATIONAL

Enrollment

15,000

Conditions

Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 years * Undergoing clinically indicated CCTA with \>64-detector row CT * Signed informed consent, including of release of medical information, long term follow-up and Health Insurance Portability and Accountability Act (HIPAA) documentation Exclusion Criteria: * Individuals unable to provide informed consent * Non-cardiac illness with life expectancy \< 2 years * Pregnancy

Locations (1)

University of Virginia

Charlottesville, Virginia, United States

Outcomes

Primary Outcomes

Coronary CT Angiography EvaluatioN For Clinical Outcomes

Examined the totality of information visualized by coronary CT angiography (CCTA) for optimal refinement of prognostic risk stratification

Time frame: June 2020- June 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.